[HONG KONG, December 19, 2022] Recently, Asia's largest biotechnology exhibition, the BIOHK2022, was held at the Hong Kong Convention and Exhibition Centre. Vice Chairman of the National Committee of the Chinese People's Political Consultative Conference (CPPCC), Mr. Leung Chunying, attended the opening event and delivered a speech. Mr. Kingsley Leung, Chairman of Great Bay Bio (hereinafter referred to as “GBB”), was invited to attend the roundtable and delivered an important speech.

BIOHK is the flagship exhibition of Hong Kong and the international biology industry, co-organized by the Hong Kong Biotechnology Organization, the BayHelix Group and Ausvic Capital, aiming to provide a global exchange platform to explore the potential and unlimited biotechnology business opportunities in Hong Kong and to allow global industry players to network. This event attracted over 200 top domestic and international exhibitors and 90 heavyweight speakers to attend. Among them were members of the Chinese People's Political Consultative Conference and leading experts in the medical field.

In a roundtable themed "Let's Make Hong Kong a Biotech Hub", Mr. Kingsley shared the innovative entrepreneurial journey of GBB in applying AI-enabled platforms to promote biotechnology innovation and solve many pain points such as long drug development cycle, high cost and low success rate, as well as promote the development of Hong Kong and international biotech industry, which was recognized and supported by many senior management and investors in the exhibition.

Mr. Kingsley Leung, Chairman of GBB (first from the right)

Mr. Kingsley Leung, Chairman of GBB (first from the right), Emmanuel Hui, CEO of Tiger Jade Pebble Accelerator (first from the left), Jack Wang, Partner of Tiger Jade Capital (second from the left), Michelle Kam, Head of Operations of Hong Kong-Shenzhen Innovation and Technology Park (second form the right)

Mr. Kingsley Leung, Chairman of GBB (left), Dr. Dongli of APX Capital (right)

About BIOHK2022

An international convention organized by HKBIO to introduce novel state-of-the-art biotech innovations from around the globe, with the purpose of providing an extensive platform to allow pioneers of the biotech industry to convene. From infectious diseases like COVID-19, to the latest cancer treatments and diagnostics to big data analytics, BIOHK2022 is an unparalleled event covering the most relevant and timely topics in biotechnology.

About Great Bay Bio

Great Bay Bio (GBB), headquartered in Hong Kong, was founded in 2019 with extensive footprint in the Greater Bay Area. Adhering to the corporate vision of “Global Bioprocessing Made Simpler and More Efficient", GBB is committed to applying AI and other cutting-edge technologies to promote bioprocessing innovations, thus solve pain points, such as long timelines, high cost and low success rate, in drug development. GBB takes improving human life, health and value as its long-term goal.

The core team of GBB is composed of global talents with expertise in medicine, pharmacy, synthetic biology and AI. With a 3000 m² R&D center and CMC platform, GBB has successfully pushed several biological drugs into the NDA stage, including national class 1 new drugs. During the three years since its establishment, GBB has applied for more than 30 patents for its AI empowered bioprocesses solutions. The resulting AI platforms were successfully commercialized, enabling GBB to establish long-term cooperation with many domestic and foreign leading enterprises.

GBB has attained the titles of National “High-Tech Enterprise” twice in a row by the National High-Tech Enterprise Certification Management Leading Group Office, “Sprouts List Most Valuable Enterprises for Investment in China for the Year 2020 by the Zero2IPO Group, “Top 50 Innovative Biotechnology Companies in Guangdong-Hong Kong-Macao Greater Bay Area Award 2020” by ZDVC RESEARCH and KPMG China, “Top 15 in the 2021 Merck Greater Bay Area Innovation Bootcamp” and “Spring class of Microsoft accelerator entrepreneurship acceleration plan in 2022”.